227 related articles for article (PubMed ID: 8578174)
21. [HCV RNA clearance after treatment with interferon-alpha in chronic hemodialysis patients with or without coinfection by HGV/HGBV-C].
Rostaing L; Izopet J; Moussion F; Alric L; Verdier D; That HT; Duffaut M; Durand D; Puel J; Suc JM
Nephrologie; 1997; 18(7):281-6. PubMed ID: 9496568
[TBL] [Abstract][Full Text] [Related]
22. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose.
Shiffman ML; Hofmann CM; Luketic VA; Sanyal AJ; Contos MJ; Mills AS
Hepatology; 1996 Jul; 24(1):21-6. PubMed ID: 8707264
[TBL] [Abstract][Full Text] [Related]
23. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
[TBL] [Abstract][Full Text] [Related]
24. Hepatic HCV-RNA as a predictor of outcome after interferon therapy in patients with chronic hepatitis C.
Kondo M; Tanaka K; Ikeda M; Arata S; Saito S; Sakaguchi T; Morimoto M; Fujii T; Mitsui K; Okazaki H; Hoshino M; Sekihara H
J Gastroenterol Hepatol; 1996 Mar; 11(3):236-40. PubMed ID: 8742919
[TBL] [Abstract][Full Text] [Related]
25. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R
Cochrane Database Syst Rev; 2012 Sep; (9):CD008516. PubMed ID: 22972122
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment.
Campistol JM; Esforzado N; Martínez J; Roselló L; Veciana L; Modol J; Casellas J; Pons M; de Las Cuevas X; Piera J; Oliva JA; Costa J; Barrera JM; Bruguera M
Nephrol Dial Transplant; 1999 Nov; 14(11):2704-9. PubMed ID: 10534516
[TBL] [Abstract][Full Text] [Related]
27. Disappearance of serum hepatitis C virus RNA within two days after one dose interferon administration is predictive for response to high-dose interferon-alpha 2b treatment for chronic hepatitis C. Keio Interferon-alpha 2b Study Group.
Saito H; Ebinuma H; Atsukawa K; Takahashi M; Masuda T; Ohishi T; Nojiri O; Mizuoka K; Ishii H
Keio J Med; 1997 Jun; 46(2):74-80. PubMed ID: 9212590
[TBL] [Abstract][Full Text] [Related]
28. High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C.
Moskovitz DN; Manoharan P; Heathcote EJ
Can J Gastroenterol; 2003 Aug; 17(8):479-82. PubMed ID: 12945008
[TBL] [Abstract][Full Text] [Related]
29. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
Keeffe EB; Hollinger FB
Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis C virus RNA in peripheral blood mononuclear cells: relation with response to interferon treatment.
Taliani G; Badolato C; Lecce R; Poliandri G; Bozza A; Duca F; Pasquazzi C; Clementi C; Furlan C; De Bac C
J Med Virol; 1995 Sep; 47(1):16-22. PubMed ID: 8551253
[TBL] [Abstract][Full Text] [Related]
31. Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.
Teuber G; Berg T; Hoffmann RM; Leifeld L; Lafrenz M; Spengler U; Pape GR; Hopf U; Zeuzem S
Digestion; 2000; 61(2):90-7. PubMed ID: 10705172
[TBL] [Abstract][Full Text] [Related]
32. Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications.
Olaso V; Córdoba J; Berenguer M; Prieto M; Lainez B; Argüello L; Valverde J; Pascual S; Gobernado M; Berenguer J
Rev Esp Enferm Dig; 1997 Jul; 89(7):531-50. PubMed ID: 9265839
[TBL] [Abstract][Full Text] [Related]
33. Long-term carriage of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C.
Kakumu S; Yoshika K; Tanaka K; Higashi Y; Kurokawa S; Hirofuji H; Kusakabe A
J Med Virol; 1993 Sep; 41(1):65-70. PubMed ID: 8228941
[TBL] [Abstract][Full Text] [Related]
34. The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C.
Shindo M; Arai K; Okuno T
J Hepatol; 1997 Mar; 26(3):492-7. PubMed ID: 9075654
[TBL] [Abstract][Full Text] [Related]
35. Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon.
Almasio PL; Di Marco V; Bonura C; Fuschi P; Camma C; Lo Iacono O; Artini M; Natoli C; Di Stefano R; Levrero M; Craxi A
Dig Dis Sci; 1999 May; 44(5):1013-9. PubMed ID: 10235612
[TBL] [Abstract][Full Text] [Related]
36. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study.
Iino S; Hino K; Kuroki T; Suzuki H; Yamamoto S
Dig Dis Sci; 1993 Apr; 38(4):612-8. PubMed ID: 8384980
[TBL] [Abstract][Full Text] [Related]
37. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
38. Biochemical and virological response of chronic hepatitis C after treatment with interferon-alpha for 6 or 12 months: predictors of sustained remission.
Papatheodoridis GV; Katsoulidou A; Touloumi G; Delladetsima JK; Hatzakis A; Tassopoulos NC
Eur J Gastroenterol Hepatol; 1996 May; 8(5):469-75. PubMed ID: 8804876
[TBL] [Abstract][Full Text] [Related]
39. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
[TBL] [Abstract][Full Text] [Related]
40. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
